Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 10/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685544 | 1.00 | HCRTR1 (0.41) | HCRTR1NAMPTACACBKDM1ACYP3A4 | |
| SCHEMBL2688235 | 0.91 | HCRTR1 (0.38) | HCRTR1NAMPTACACBKDM1ACYP3A4 | |
| SCHEMBL2688236 | 0.91 | HCRTR1 (0.38) | HCRTR1NAMPTACACBKDM1ACYP3A4 | |
| SCHEMBL2688280 | 0.85 | CYP3A4 (0.50) | NAMPTACACBKDM1ACYP3A4PRMT5 | |
| SCHEMBL2688278 | 0.85 | CYP3A4 (0.50) | NAMPTACACBKDM1ACYP3A4PRMT5 | |
| SCHEMBL2685111 | 0.84 | CYP3A4 (0.42) | HCRTR1NAMPTACACBKDM1ACYP3A4 | |
| SCHEMBL2685109 | 0.84 | CYP3A4 (0.42) | HCRTR1NAMPTACACBKDM1ACYP3A4 | |
| SCHEMBL2686484 | 0.82 | CYP3A4 (0.40) | NAMPTACACBKDM1ACYP3A4PRMT5 | |
| SCHEMBL2686483 | 0.82 | CYP3A4 (0.40) | NAMPTACACBKDM1ACYP3A4PRMT5 | |
| SCHEMBL935329 | 0.81 | HCRTR1 (0.39) | HCRTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | HCRTR1 15/4885NAMPT 1643/4885ACACB 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.